A Cave in France Changes What We Thought We Knew About Neanderthals

A cave in France contains man’s earliest-known structures that had to be built by Neanderthals who were believed to be incapable of such things.

Entrance to the cave
Image source: yannvdb/Wikimedia Commons

In a French cave deep underground, scientists have discovered what appear to be 176,000-year-old man-made structures. That's 150,000 years earlier than any that have been discovered anywhere before. And they could only have been built by Neanderthals, people who were never before considered capable of such a thing.


This is going to force a major shift in the way we see these early hominids. Researchers had thought that Neanderthals were profoundly primitive, and just barely human. This cave in France's Aveyron Valley changes all that: It's suddenly obvious that Neanderthals were not quite so unlike us.

According to The Atlantic, Bruniquel Cave was first explored in 1990 by Bruno Kowalsczewski, who was 15 at the time. He'd spent three years digging away at rubble covering a space through which his father felt air moving.

Some members of a local caving club managed to squeeze through the narrow, 30-meter long tunnel Kowalsczewski had dug to arrive in a passageway. They followed it past pools of water and old animal bones for over 330 meters before coming into a large chamber and a scene they had no reason to expect: Stalagmites that someone had broken into hundreds of small pieces, most of which were arranged into two rings—one roughly 6 meters across, and one 2 meters wide—with the remaining pieces stacked into one of four piles or leaning against the rings. There were also indications of fires and burnt bones.

Image source: Etienne FABRE - SSAC

What the?

A professional archeologist, Francois Rouzaud, determined with carbon dating that a burnt bear bone found in the chamber was 47,600 years old, which made the stalagmite structures older than any known cave painting. It also put the cave squarely within the age of the Neanderthals since they were the only humans in France that early. No one had suspected them of being capable of constructing complex forms or doing anything that far underground.

After Rouzard suddenly died in 1999, exploration at the cave stopped until life-long caver Sophie Verheyden, vacationing in the area, heard about it and decided to try and uranium-date the stalagmites inside.

The team she assembled eventually determined that the stalagmites had been broken up by people 176,000 years ago, way farther back even than Rouzard had supposed.

There weren't any signs that Neanderthals lived in the cave, so it's a mystery what they were up to down there. Verheyden thinks it's unlikely that a solitary artist created the tableaux, and so an organized group of skilled workers must've been involved. And “When you see such a structure so far into the cave, you think of something cultural or religious, but that's not proven," Verheyden told The Atlantic.

Whatever they built, the Bruniquel Cave reveals some big surprises about Neanderthals: They had fire, they built things, and likely used tools. Add this to recent discoveries that suggest they buried their dead, made art, and maybe even had language, and these mysterious proto-humans start looking a lot more familiar. A lot more like homo sapiens, and a lot more like distant cousins lost to history.

Paul Hudson/Flickr

U.S. Navy controls inventions that claim to change "fabric of reality"

Inventions with revolutionary potential made by a mysterious aerospace engineer for the U.S. Navy come to light.

U.S. Navy ships

Credit: Getty Images
Surprising Science
  • U.S. Navy holds patents for enigmatic inventions by aerospace engineer Dr. Salvatore Pais.
  • Pais came up with technology that can "engineer" reality, devising an ultrafast craft, a fusion reactor, and more.
  • While mostly theoretical at this point, the inventions could transform energy, space, and military sectors.
Keep reading Show less

Why so gassy? Mysterious methane detected on Saturn’s moon

Scientists do not know what is causing the overabundance of the gas.

An impression of NASA's Cassini spacecraft flying through a water plume on the surface of Saturn's moon Enceladus.

Credit: NASA
Surprising Science
  • A new study looked to understand the source of methane on Saturn's moon Enceladus.
  • The scientists used computer models with data from the Cassini spacecraft.
  • The explanation could lie in alien organisms or non-biological processes.
Keep reading Show less

CRISPR therapy cures first genetic disorder inside the body

It marks a breakthrough in using gene editing to treat diseases.

Credit: National Cancer Institute via Unsplash
Technology & Innovation

This article was originally published by our sister site, Freethink.

For the first time, researchers appear to have effectively treated a genetic disorder by directly injecting a CRISPR therapy into patients' bloodstreams — overcoming one of the biggest hurdles to curing diseases with the gene editing technology.

The therapy appears to be astonishingly effective, editing nearly every cell in the liver to stop a disease-causing mutation.

The challenge: CRISPR gives us the ability to correct genetic mutations, and given that such mutations are responsible for more than 6,000 human diseases, the tech has the potential to dramatically improve human health.

One way to use CRISPR to treat diseases is to remove affected cells from a patient, edit out the mutation in the lab, and place the cells back in the body to replicate — that's how one team functionally cured people with the blood disorder sickle cell anemia, editing and then infusing bone marrow cells.

Bone marrow is a special case, though, and many mutations cause disease in organs that are harder to fix.

Another option is to insert the CRISPR system itself into the body so that it can make edits directly in the affected organs (that's only been attempted once, in an ongoing study in which people had a CRISPR therapy injected into their eyes to treat a rare vision disorder).

Injecting a CRISPR therapy right into the bloodstream has been a problem, though, because the therapy has to find the right cells to edit. An inherited mutation will be in the DNA of every cell of your body, but if it only causes disease in the liver, you don't want your therapy being used up in the pancreas or kidneys.

A new CRISPR therapy: Now, researchers from Intellia Therapeutics and Regeneron Pharmaceuticals have demonstrated for the first time that a CRISPR therapy delivered into the bloodstream can travel to desired tissues to make edits.

We can overcome one of the biggest challenges with applying CRISPR clinically.

—JENNIFER DOUDNA

"This is a major milestone for patients," Jennifer Doudna, co-developer of CRISPR, who wasn't involved in the trial, told NPR.

"While these are early data, they show us that we can overcome one of the biggest challenges with applying CRISPR clinically so far, which is being able to deliver it systemically and get it to the right place," she continued.

What they did: During a phase 1 clinical trial, Intellia researchers injected a CRISPR therapy dubbed NTLA-2001 into the bloodstreams of six people with a rare, potentially fatal genetic disorder called transthyretin amyloidosis.

The livers of people with transthyretin amyloidosis produce a destructive protein, and the CRISPR therapy was designed to target the gene that makes the protein and halt its production. After just one injection of NTLA-2001, the three patients given a higher dose saw their levels of the protein drop by 80% to 96%.

A better option: The CRISPR therapy produced only mild adverse effects and did lower the protein levels, but we don't know yet if the effect will be permanent. It'll also be a few months before we know if the therapy can alleviate the symptoms of transthyretin amyloidosis.

This is a wonderful day for the future of gene-editing as a medicine.

—FYODOR URNOV

If everything goes as hoped, though, NTLA-2001 could one day offer a better treatment option for transthyretin amyloidosis than a currently approved medication, patisiran, which only reduces toxic protein levels by 81% and must be injected regularly.

Looking ahead: Even more exciting than NTLA-2001's potential impact on transthyretin amyloidosis, though, is the knowledge that we may be able to use CRISPR injections to treat other genetic disorders that are difficult to target directly, such as heart or brain diseases.

"This is a wonderful day for the future of gene-editing as a medicine," Fyodor Urnov, a UC Berkeley professor of genetics, who wasn't involved in the trial, told NPR. "We as a species are watching this remarkable new show called: our gene-edited future."

Quantcast